Stockholder Alert: Robbins LLP Informs Investors of the Class Action Lawsuit Filed Against Gritstone Bio, Inc.

Group 1 - Gritstone entered into a contract with BARDA for a 10,000 participant Phase 2b study of its COVID-19 vaccine candidate, expected to launch in Q1 2024 [1] - The company allegedly failed to disclose its inability to launch the study on time, which could impair its ability to secure external funding and maintain its financial position [2] - On February 12, 2024, Gritstone announced a delay of the study launch to Fall 2024, followed by a 40% workforce reduction due to the lack of anticipated external funding [3] Group 2 - A class action was filed on behalf of investors who purchased Gritstone securities between March 9, 2023, and February 29, 2024, alleging misleading information regarding the Phase 2b study [9][10] - Shareholders interested in serving as lead plaintiffs must file motions by August 6, 2024, and can remain absent class members if they choose not to participate [4]